Bolt Biotherapeutics, Inc. (BOLT)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $6.54
- As of
Kresmion compiles this page from BOLT's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Bolt Biotherapeutics, Inc. (BOLT): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-23.
See the full BOLT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BOLT on one page. Preview it with sample data, then open it live with a free account.
Preview the BOLT dossierActive events for BOLT
- mediumEarnings below estimates
Q2-2026: Missed consensus by 32.3%, EPS $-4.57 vs $-3.4544 estimate
- medium13F: new position
CITADEL ADVISORS LLC new position in BOLT
- mediumEarnings above estimates
Q2-2025: Beat consensus by 32.2% - EPS $-4.46 vs $-6.579 estimate
- mediumEarnings below estimates
Q1-2026: Missed consensus by 48.3% - EPS $-4.31 vs $-2.907 estimate
- mediumEarnings above estimates
Beat consensus by 32.2% - EPS $-4.46 vs $-6.579 estimate
FREE, NO ACCOUNT
Every event on BOLT, as it fires
You are seeing 5 of 8 events recorded on BOLT since 2026-05-16.
The five above landed across 4 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
BOLT positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 097702203 · 2026Q2 | $380K | 0.00% |
| CITADEL ADVISORS LLC FundCUSIP 097702203 · 2026Q2 | $219K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BOLT
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
BOLT's 10-Q filed Aug 11, 2026 states:
The Company believes that this raises substantial doubt about its ability to continue as a going concern within one year after the issuance of the unaudited condensed consolidated financial statements.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on BOLT
BOLT mentioned in Kresmion daily briefs
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in BOLT on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on BOLT in the last 180 days.
Upstream: SEC EDGAR filings for BOLT
Kresmion, "Bolt Biotherapeutics, Inc. (BOLT) institutional holdings and SEC filings", data as of 2026-10-23, https://kresmion.com/research/BOLT. Upstream data: SEC EDGAR filings for BOLT.
Link to this data (HTML):
<a href="https://kresmion.com/research/BOLT">Bolt Biotherapeutics, Inc. (BOLT) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow BOLT on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to BOLT for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.